Hinge Health shares rose sharply in the second quarter after the company reported a substantial earnings beat and raised its full-year guidance, driven by accelerating bookings as clients added more eligible lives and yields improved. The Meridian Small Cap Growth Fund highlighted the healthcare technology company in its Q2 2026 investor letter, citing its dominant position in a large, underpenetrated musculoskeletal care market, improving per-member economics, and a widening product suite. Management reinforced the momentum at its inaugural investor day with new long-term growth and margin targets and strong early reception for its new migraine product. The fund noted the stock advanced despite broader market wariness toward digital health. Hinge Health closed at $74.06 per share on July 29, 2026, with a market capitalization of $5.73 billion.
Hinge Health, Inc.Accelerating bookings as clients added more eligible lives and yields improved, plus strong early reception for new migraine product.